Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
PDGF-C Antibody
NCTP12274
Description: Rabbit polyclonal to human PDGF-C
Application: ELISA, WB, IHC
Reactivity: Human, mouse, rat
Catalog #: NCTP12274
$380.00
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human, mouse, rat. Other species not tested. |
| Isotype | IgG |
| Immunogen | 158 aa recombinant protein from near the C terminal of human PDGF-C. |
| Accession # | Q9NRA1 |
| Alternative Names | Platelet-derived growth factor C; Fallotein; Spinal cord-derived growth factor; SCDGF; VEGF-E |
| Purification | Purified by peptide affinity column. |
| Formulation | Lyophilized with 0.5% BSA and 0.02% NaN3. |
| Size | 200µl |
| APPLICATION | |
| ELISA | 1:20,000 – 1:80,000 |
| Western Blot | 1:200 – 1:1,000 |
| Immunohistochemistry | 1:50 – 1:200 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Crawford,Y., Kasman,I., Yu,L., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15 (1), 21-34 (2009). |